Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)

Comprehensive Characterization Of Right Ventricular Performance And Afterload In Patients With Pulmonary Arterial Hypertension Undergoing Initiation And Rapid Dose Escalation Of Treprostinil

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02074449

Acronym

ISS

Enrollment

Registered

2014-02-28

Start date

2012-12-31

Completion date

2015-12-31

Last updated

2016-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension

Keywords

Pulmonary Arterial Hypertension, Right Ventricular Performance, Treprostinil, Remodulin

Brief summary

Patients with pulmonary arterial hypertension (PAH) are at much higher risk of death if the RV (right ventricle) is weak. The purpose of this study is to get a better understanding of the factors that determine RV adaptation and how the RV compensates on therapy. The investigator is also interested in how Remodulin (treprostinil) infused over a short period (approximately 48-72 hours) affects the patient's quality of life, medical care, and personal health behaviors. Treprostinil, also known as Remodulin, has been approved by the US Food and Drug Administration for use in the treatment of PAH. The investigator has been treating patients with Remodulin by rapid infusion (over 48 hours) for over 6 years. The investigator would like to establish this practice as safe and effective for the benefit of other centers that treat PAH.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with clinically suspected World Health Organization (WHO) group I PAH * Patients with New York Heart Association/WHO functional class II-IV * Patients with mean pulmonary artery pressure \>25 mmHg, pulmonary capillary wedge pressure \</=15 mmHg, and pulmonary vascular resistance \>3 wood units * Age \>18 and \<80 * No evidence of active ischemic heart disease

Exclusion criteria

* Left ventricular ejection fraction \<50% * Patients with significant restrictive lung disease (FVC \<60% predicted) and/or significant obstructive lung disease (FEV1 \<55% predicted) within 1 year of enrollment if pulmonary function testing is available * Patients with significant, investigator-determined parenchymal lung disease on chest x-ray or CT of the chest * History of pulmonary embolism within the last three months or chronic pulmonary embolism * Poorly interpretable grey scale echocardiographic images * Contraindications to right heart catheterization * Moderate-severe aortic and mitral valve abnormality * Active or previous use of pulmonary vasoactive medication within the previous 12 weeks * Renal failure with serum creatinine clearance \<30 ml/hr * High-probability ventilation-perfusion scan

Design outcomes

Primary

Measure	Time frame
Measurement of change in RV coupling index on treprostinil between baseline, titration at 48-72 hours, and 3 months.	3 months

Countries

United States

Outcome results